Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL's long-standing mission to deliver targeted, life-saving treatments that address unmet clinical ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

The Fellows of the AACR Academy have elected Elaine V. Fuchs, PhD, FAACR, as their next President. She will assume the ...